Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record.

Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma

Open access
Esquivel, Ann, Busse, William W., Calatroni, Agustin, Togias, Alkis G., Grindle, Kristine G., Bochkov, Yury A., Gruchalla, Rebecca S., Kattan, Meyer, Kercsmar, Carolyn M., Khurana Hershey, G., Kim, Haejin, Lebeau, Petra, Liu, Andrew H., Szefler, Stanley J., Teach, Stephen J., West, Joseph B., Wildfire, Jeremy, Pongracic, Jaqueline A., Gern, James E. · 2017 · American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVES: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma. METHODS: In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression. MEASUREMENTS AND MAIN RESULTS: RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84). CONCLUSIONS: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.201701-0120oc

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 251

Metadata

Authors
Esquivel, A., Busse, W. W., Calatroni, A., Togias, A. G., Grindle, K. G., Bochkov, Y. A., Gruchalla, R. S., Kattan, M., Kercsmar, C. M., Khurana Hershey, G., Kim, H., Lebeau, P., Liu, A. H., Szefler, S. J., Teach, S. J., West, J. B., Wildfire, J., Pongracic, J. A., & Gern, J. E.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2017-10-15
Volume
196
Issue
8
Pages
985-992
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2626956924
Cited by
251
References
0
FWCI
19.23
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. https://app.cochat.ai/papers/10.1164/rccm.201701-0120oc
The paper
Esquivel, A., Busse, W. W., Calatroni, A., Togias, A. G., Grindle, K. G., Bochkov, Y. A., Gruchalla, R. S., Kattan, M., Kercsmar, C. M., Khurana Hershey, G., Kim, H., Lebeau, P., Liu, A. H., Szefler, S. J., Teach, S. J., West, J. B., Wildfire, J., Pongracic, J. A., & Gern, J. E. (2017). Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201701-0120oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.